Navigation Links
Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
Date:4/23/2013

Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic acid) and activating peroxisome proliferator-activator receptorγ (PPARγ) with the thiazolidinedione rosiglitazone on the pathological progression of cardiometabolic syndrome. Cardiometabolic syndrome occurs with obesity and hypertension increasing the risks for cardiovascular disease and causing significant and rapidly progressive kidney disease. The findings, which appear in the December 2012 issue of Experimental Biology and Medicine, demonstrate that sEH inhibition and PPARγ activation in combination had the greatest beneficial effects on the multi-disease features and progression of kidney disease associated with cardiometabolic syndrome.

"Inhibitors of sEH have recently reached a point where their ability to combat cardiovascular and kidney diseases can be determined in humans", states Dr. Imig. "In this study we show that when used in combination with a PPARγ agonist therapy for cardiometabolic syndrome that there is a synergistic effect to decrease cardiovascular risk factors and progressive kidney disease. Another potential positive aspect of this combination therapy is that sEH inhibition has beneficial actions to counteract the edema and congestive heart failure that occurs in patients treated long-term with PPARγagonists."

Future studies would include combinational chemistry approaches to design and synthesize drugs with dual sEH inhibitory and PPARγ agonistic activities. Dr. Hammock states, "these approaches are currently being done by his laboratory and others". He also says "that combining sEH inhibition not just with PPARγ but also with other therapies for cardiovascular, inflammatory, and renal diseases are on the horizon and have therapeutic potential as both drug combinations and dual sEH inhibitors with PPARγ activity for treating cardiometabolic syndrome."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said, " This study by John Imig and Bruce Hammack, performed on spontaneous hypertensive and spontaneous hypertensive obese rat models, suggests that a combined therapy with epoxide hydrolase inhibitors and thiazolidinediones may prove to be efficacious in treatment of the multi-disease characteristics of cardiometabolic syndrome. "


'/>"/>

Contact: John Imig
jdimig@mcw.edu
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
2. Novel test identifies patients most likely to benefit from ALK inhibition therapy
3. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
4. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
5. Palliative radiotherapy for bone metastases in elderly patients improves quality of life
6. Physical Therapy Exercises
7. How “Post Rehab Essentials” Helps People Learn About Post Rehab – V kool
8. Intensity modulated radiotherapy reduces side effects in patients with early breast cancer
9. New radiotherapy approach reduces symptoms of dry mouth in patients with head and neck cancers
10. 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
11. Early cognitive behavioural therapy reduces risk of psychosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... San Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... a week long softball camp from July 24th – 27th for girls aged 10-18. ... The camp is held at the beautiful Clark V. Whited Complex, one of the ...
(Date:4/29/2016)... ... 29, 2016 , ... HEALTHCAREfirst , the leading provider ... Deyta Analytics, recently announced the recipients of the fourth annual Hospice Honors, a ... from the caregiver’s point of view. The official list of recipients was unveiled ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec ... held May 16th to 18th at the Broward County Convention Center. The event ... to collaborate on best practices in public facility management. Intellitec Solutions will highlight ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and ... highlighting inconsistencies of adding BC and AD, saying it is time to set the ... After Christ. Yisrayl says this simply cannot possibly be true and offers explanation. , ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... , April 27, 2016 ... USD 2.14 billion by 2022, according to a ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... affecting the efficiency and accuracy delivered by the ... demand for novel urinalysis instruments and consumables. For ...
Breaking Medicine Technology: